Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma. - Wikidata - wikimedia - TriplyDB

Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma.

Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma.

http://www.wikidata.org/entity/Q36825081

about

Medical interventions for the prevention of platinum-induced hearing loss in children with cancer Medical interventions for the prevention of platinum-induced hearing loss in children with cancer Medical interventions for the prevention of platinum-induced hearing loss in children with cancer Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale.Cisplatin ototoxicity and protection: clinical and experimental studies Cisplatin and aminoglycoside antibiotics: hearing loss and its prevention.Carboplatin-associated ototoxicity in children with retinoblastoma.Evaluation of amifostine for protection against cisplatin-induced serious hearing loss in children treated for average-risk or high-risk medulloblastoma.Clinical pharmacokinetics of amifostine and WR1065 in pediatric patients with medulloblastoma.Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy.Ototoxicity evaluation in medulloblastoma patients treated with involved field boost using intensity-modulated radiation therapy (IMRT): a retrospective review Transtympanic administration of short interfering (si)RNA for the NOX3 isoform of NADPH oxidase protects against cisplatin-induced hearing loss in the rat.Relevance of historical therapeutic approaches to the contemporary treatment of pediatric solid tumors.N-acetylcysteine chemoprotection without decreased cisplatin antitumor efficacy in pediatric tumor models.Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss Concordance between the chang and the International Society of Pediatric Oncology (SIOP) ototoxicity grading scales in patients treated with cisplatin for medulloblastoma.Cumulative cisplatin dose is not associated with event-free or overall survival in children with newly diagnosed average-risk medulloblastoma treated with cisplatin based adjuvant chemotherapy: report from the Children's Oncology Group.New Insights into Potential Prevention and Management Options for Chemotherapy-Induced Peripheral Neuropathy.SOD2 genetic variant associated with treatment-related ototoxicity in cisplatin-treated pediatric medulloblastoma Glutathione S-transferase P1 single nucleotide polymorphism predicts permanent ototoxicity in children with medulloblastoma.Systemic cancer therapy: achievements and challenges that lie ahead Genetic variants associated with cisplatin-induced ototoxicity.The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer.Pharmacotherapy of neuroblastoma.Ten challenges in the management of neuroblastoma.Ototoxicity (cochleotoxicity) classifications: A review.The role of germline variants in chemotherapy outcome in brain tumors: a systematic review of pharmacogenetic studies.Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial.Role of TPMT and COMT genetic variation in cisplatin-induced ototoxicity.Mechanisms of Cisplatin-Induced Ototoxicity and Otoprotection.Acquired sensorineural hearing loss in children: current research and therapeutic perspectives.Audiological monitoring in Swiss childhood cancer patients.DNA methylation of a novel PAK4 locus influences ototoxicity susceptibility following cisplatin and radiation therapy for pediatric embryonal tumors.Ototoxicity: A Challenge in Diagnosis and Treatment.CDK2 inhibitors as candidate therapeutics for cisplatin- and noise-induced hearing loss.Early cisplatin induced ototoxicity profile may predict the need for hearing support in children with medulloblastoma.Hearing loss among survivors of childhood brain tumors treated with an irradiation-sparing approach.Economic impact of a genetic test for cisplatin-induced ototoxicity.Anatomical and physiological basis for the allometric scaling of cisplatin clearance in dogs.

P2860

Q24194929-F4F1A9C0-2F6E-4063-A36C-8D9269D06668 Q24197812-73C278D3-4450-4DCA-BCBF-74195A292909 Q24236069-A52D8324-FB96-4DBF-B16E-D96904BE243E Q24615296-54DE54E5-2C2A-4C87-A13B-F62DF756B931 Q24628775-4FF1B385-07B2-48A4-9C38-503253A4809C Q30447637-2F8B16A5-C6B4-4D36-B0D2-DA6BD0678BFA Q30513911-83458063-57D0-43D4-BD9B-6BE3318013F5 Q30578179-23559463-F2A8-4B12-93EF-73E3193616E8 Q33638876-14E030A1-4FB1-4666-BDD1-E29090E954AE Q33744706-CD77FDA6-9144-4D73-8001-F609FDC85B29 Q33985538-389606CA-7DE1-4BD2-9E34-2EEB1C4F2C3F Q34110153-0D8C4765-77A1-4F36-B1F7-7019147EEC94 Q34589401-D9A74677-8513-4C50-A027-6BBE239062C3 Q35071886-1E97C43E-EF92-442C-8460-7C604366345B Q35172741-0CDD9CEA-AEF8-4E27-8396-B42094094BD1 Q35211949-3EC977BA-C508-49D9-8F4C-5CCFC144DF57 Q36114760-E49A05FB-E0E8-49ED-BFB8-F5A090181881 Q36226275-30341411-0777-429B-8ABE-E06DD212FCBD Q36358551-20AC6CC4-9951-4797-A1D3-1424E0CE4664 Q36546317-FA53ABCA-24E6-41DE-B4A7-726B656B6A1A Q36821958-2041D042-1529-426D-89B0-7BBD3B53A5B9 Q37293994-5A225BEE-9E74-447A-A076-C5E1471D88B3 Q37444522-CB3B2602-C010-4154-9336-FDF83B492FEA Q37735199-E9F9BDB0-E064-4D87-A1DC-5ED132DBC6CA Q38029366-BBBA6A8B-EEA6-42FF-BEA7-C522D2F34B0A Q38653146-C0BDD34B-B853-48AB-9781-EFAF43BBB0A8 Q38739253-6EF46535-B8AD-4E03-A134-8AC5C8132BE7 Q38964704-AFAE369C-4D5D-4A80-9496-71BF3AFE47D9 Q40443233-8CC68E13-FC0D-41CC-B279-A5548134C83C Q45354484-A94E90ED-97FF-43B4-8874-EE7A60893234 Q46256727-110110AF-4415-414C-847B-721324B57E73 Q47554578-8B10320B-42CE-4F47-A388-A751CA6B8C14 Q47577823-4A83B123-9F18-4607-9E1D-809727688FE4 Q48659411-8C5F7F6A-4DC4-4124-885E-BAA549427E4B Q50300972-33154270-657B-4450-83D6-24A4D2FA73D9 Q50420474-6FE45905-071E-436F-B554-7E546A484184 Q50428964-50E9755D-7826-404E-8F03-FEB2F36447CC Q50433278-824A573A-7E49-47E5-9FA1-D97C46A1F926 Q50434327-65A41396-61D2-4EEF-AFE2-66AB3E51BF13 Q50798269-846B405E-F068-47EE-83D9-49F3617B44D3

P2860

Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma.

http://www.wikidata.org/entity/Q36825081

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Amifostine protects against ci ...... average-risk medulloblastoma.

@en

type

label

Amifostine protects against ci ...... average-risk medulloblastoma.

@en

prefLabel

Amifostine protects against ci ...... average-risk medulloblastoma.

@en

P1433

Q36825081-148AF805-B869-4221-9D02-1ADAD8AB9653

P1476

Q36825081-4864BED9-1610-449F-9A2B-0C1AA0D94BCD

P2093

Q36825081-002A774C-A7A5-45B2-8BF8-3094F8B5C0FB

Q36825081-2470EF5D-C016-4955-B6EF-37A33DB3A9CD

Q36825081-345460CA-F06D-4BBF-BE0E-FA57C43204B5

Q36825081-3719E7D7-5E92-4D9F-A745-861D966FCD93

Q36825081-3EF76FED-0312-4823-8A82-E8BE54657ED7

Q36825081-4B605C39-50EC-48F5-84A7-8E015558716C

Q36825081-530D20E7-EF44-4960-8A84-BF87054425CF

Q36825081-59711621-2341-4C96-BBA9-451AC1D93296

Q36825081-63DF97C1-93A2-4FAD-A542-BB4C3A8151AB

Q36825081-65D54BFC-A522-48E2-8BFF-99F67A718DD4

P2860

Q36825081-036A8C2A-39F8-47F9-88B3-07DD99D9F88C

Q36825081-0A7EDB80-D44F-48CC-A772-4DB387A10E68

Q36825081-1554C277-CB3D-4CC5-AE60-7BC61A2DACBD

Q36825081-155B79B7-A096-4BA0-81A2-769DBB170CAA

Q36825081-22F989A3-3E56-48C7-ABF2-BD9CBDEEEB24

Q36825081-2F33FED6-DEAA-428A-B70C-5EA5142A9666

Q36825081-3A0B7D93-6888-423E-8F31-08A7B0FBFA4B

Q36825081-3CD99AE3-B39C-4608-B676-033D820A0307

Q36825081-3DB444EB-3F0F-47EC-89B0-068C589A202A

Q36825081-45C1C428-14CE-41D2-8C91-B4A14691D906

P304

Q36825081-1F7DF82B-EB46-4356-823A-5F9141A801FF

P31

Q36825081-7153A05B-B4C7-4C7B-B929-9954514FD595

P356

Q36825081-38550E4D-77E7-44B5-A981-E419460A2628

P407

Q36825081-C9015488-1A5F-45DC-94A8-D315D3060C59

P433

Q36825081-0F2D3B76-0B43-4F5E-A0D7-67C097342AC5

P478

Q36825081-F2434368-1993-441B-B563-883135A0CB1E

P50

Q36825081-7B7DF89D-2B73-4C22-A9F9-102AB4E19AB2

Q36825081-8942CA95-F3EF-432E-986F-C10BBA05895D

Q36825081-9BAF7854-AAFE-4848-986A-0D2EE84B6508

P577

Q36825081-E92149D5-0958-4641-93F0-7918E90D9D54

P698

Q36825081-14EF8BB9-3635-44E1-8121-40C6C3A05830

P921

Q36825081-A7D89C11-0BF3-43A8-8035-B047A2CC9209

P932

Q36825081-92B8DF6D-175F-4C33-9F12-3B23E84D0970

P356

JCO.2007.14.3974

P1433

Journal of Clinical Oncology

P1476

Amifostine protects against ci ...... average-risk medulloblastoma.

@en

P2093

Alberto Broniscer

http://www.w3.org/2001/XMLSchema#string

Amar Gajjar

http://www.w3.org/2001/XMLSchema#string

Brannon Morris

http://www.w3.org/2001/XMLSchema#string

Clinton F Stewart

http://www.w3.org/2001/XMLSchema#string

Dana Wallace

http://www.w3.org/2001/XMLSchema#string

David Ashley

http://www.w3.org/2001/XMLSchema#string

Gregory A Hale

http://www.w3.org/2001/XMLSchema#string

James M Boyett

http://www.w3.org/2001/XMLSchema#string

Kimberly A Kasow

http://www.w3.org/2001/XMLSchema#string

Larry E Kun

http://www.w3.org/2001/XMLSchema#string

P2860

Final report of the phase I trial of single-dose WR-2721 [S-2-(3-aminopropylamino)ethylphosphorothioic acid]

Longitudinal data analysis for discrete and continuous outcomes

Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer. EORTC Head and Neck Cooperative Group.

Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: a Children's Oncology Group study.

Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: a randomised phase II study

The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine.

Hearing loss as a late complication of radiotherapy in children with brain tumors.

Future opportunities in preventing cisplatin induced ototoxicity.

Comparison of five agents in protecting the cochlea against the ototoxic effects of cisplatin in the hamster.

Amifostine: potential for clinically useful cytoprotection.

P304

3749-3755

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2007.14.3974

http://www.w3.org/2001/XMLSchema#string

P407

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P50

Murali Chintagumpala

Sridharan Gururangan

P577

2008-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18669462

http://www.w3.org/2001/XMLSchema#string

P921

medulloblastoma

P932

2504739

http://www.w3.org/2001/XMLSchema#string